None listed
Conditions
Interventions
Intervention1: Naproxen Sodium Tablet 550 mg (Test Product) by Fourrts (India) Laboratories Pvt. Limited: After an overnight fast of at least 10.00 hours, a single dose of either the study drug Naprox
Sponsors
Fourrts (India) Laboratories Pvt. limited
ICBio Clinical Research Private limited
Eligibility
Inclusion criteria
Inclusion criteria: 1) Willing to provide written informed consent for participation in the study, and an ability to comprehend the nature and purpose of the study. 2) Willing to be available for the entire study period and to comply with protocol requirements. 3) Normal, healthy, adult, human subject of 18-55 years (both inclusive) of age. 4) Body mass index in the range of 18.5 30.0 kg-m2 (both inclusive). 5) Healthy volunteers who are clinically non-anemic will be included as per the discretion of PI/CI/Physician. 6) Normal health status as determined by baseline medical and medication history, at the time of screening and vital signs (blood pressure, pulse rate, respiratory rate and axillary/body temperature) measurements at the time screening as well as throughout the study. 7) With normal or clinically non-significant laboratory values as determined by hematological, biochemistry tests and urine analysis. 8) With a normal or clinically non-significant 12-lead ECG. 9) With a negative test for Human Immunodeficiency Virus (HIV) type I/II antibodies or Hepatitis B surface antigen (HBsAg) or Hepatitis C virus antibodies. 10) Non-smokers and willing to abstain from smoking or chewing any tobacco containing product at least 72.00 hours prior to dosing if have history of smoking habit and throughout the sampling points. 11) Male volunteer willing to use appropriate contraceptive measures to ensure that his female partner will not get pregnant for at least 15 days before 1st dosing till 15 days post last-dose/ entire study period. 12) In case of female subjects: 13) Negative urine pregnancy test during screening and negative serum beta-hCG test at check-in of each study period. 14) Female subjects with childbearing potential or those within their first two years of onset of menopausal syndrome must either abstain from sexual intercourse or using acceptable methods of birth control for at least 15 days before 1st dosing till 15 days post last-dose/ entire study period [Acceptable birth control methods include barrier methods such as diaphragm/condom with or without spermicide or who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) has been performed]. 15) Able to read and understand the Informed Consent Document as a whole and communicate effectively if required.
Exclusion criteria
Exclusion criteria: 1)Incapable of understanding the informed consent information 2) History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder. 3) History or presence of severe renal dysfunction, including those receiving dialysis and hepatic dysfunction. 4) History or presence of active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities. 5) History or presence of pre-existing gallbladder disease. 6) History or presence of mortality and coronary heart disease morbidity 7) Use of antihypertensive drugs and pressor Agents (e.g. dopamine, dobutamine), use of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine), use of monoamine oxidase Inhibitors in the previous 30 days before first drug administration and till the completion of the study. 8) History or presence of bronchospasm, asthma, urticaria associated with acetylsalicylic acid or other non-steroidal anti-inflammatory drugs. 9) History or presence 10) History or presence of thyroid disease, adrenal dysfunction, organic intracranial lesion. 11) History or presence of ulcerative colitis. 12) History or presence of cancer. 13) Difficulty with donating blood. 14) Difficulty in swallowing solids like tablets. 15) Use of any prescribed medication [including herbal medicines, vitamin supplements, oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as aspirin, antacids or cholestyramine, hydantoin derivatives or sulphonylurea derivatives, probenecid, methotrexate, furosemide, lithium, beta blockers, ACE inhibitors and Angiotensin Receptor Antagonist and Steroids] or vitamins, herbal products and OTC medicinal products during two weeks prior to study initiation. 16) Subject chewed tobacco / consumed pan or pan masala, gutkha, masala (containing beetle nut and tobacco), xanthine-containing foods or beverages (coffee, tea, chocolate, and caffeine-containing sodas, colas, etc) for 48.00 hours prior to initiation of the study till the end of the study. 17) Subjects consumed grape fruit juice and poppy containing foods for 72.00 hours prior to initiation of the study till the end of the study. 18) Major illness during the 180 days before screening. 19) Participation in a drug research study within 90 days of screening. 20) Donation of blood within 90 days of screening. 21) Positive screening test result for any one or more of the following: HIV, Hepatitis B, Hepatitis C and VDRL. 22) Positive result for urinary screen test for drugs of abuse (amphetamines, morphine, benzodiazepines, marijuana, cocaine and barbiturate). 23) Subjects with positive test results for urine pregnancy test for female subjects. 24) History or presence of easy bruising or bleeding. 25) Abnormal diet patterns (for any reason) during the four weeks preceding the study, including fasting, high protein, low sodium diets etc. 26) Use of any hormone replacement therapy within 3 months prior to the first dose of study medication. 27) A depot injection or implant of any drug within 3 months prior to the first dose of study medication. 28) Pregnant woman and nursing mothers. 29) History of allerg
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the rate and extent of absorption of Naproxen Sodium Tablet 550 mg by Fourrts (India) Laboratories Pvt. Limited with Apranax 550 mg (Naproxen Sodium) of Atnahs Pharma Netherlands B.V Copenhangen Towers, Denmark. in healthy adult human subjects under fasting conditions.Timepoint: The venous blood samples will be withdrawn at pre-dose (0.00 hour) and 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 3.00, 3.50, 4.00, 6.00, 8.00, 10.00, 12.00, 24.00, 48.00 and 72.00 hours post-dose following drug administration in each period | — |
Secondary
| Measure | Time frame |
|---|---|
| To monitor the safety and tolerability of the study subjects after administration of Naproxen Sodium Tablet 550 mg in healthy, adult, human subjects, under fasting conditionsTimepoint: Vital signs (blood pressure, pulse rate, respiratory rate and axillary/body temperature) measurement station Before check-in, at Pre-dose 0.00 (within 2.00 hrs before dosing), at 3.00, 7.00 and 11.00 hrs after dosing (within 60 min of scheduled time of recording), at the time of checkout in each period and each ambulatory visit in each period. The well-being of subjects will be ascertained at each vital sign measurement. | — |
Countries
India
Contacts
Public ContactDr Lakshmikar B V
ICBio Clinical Research Private limited
Outcome results
None listed